- Cogent Biosciences (COGT, Financial) presented promising preclinical data for four key oncology programs at the AACR 2025 Annual Meeting.
- The KRAS inhibitor showed a 90% tumor growth inhibition in mouse models, while CGT4859 is progressing in Phase 1 trials.
- Cogent expanded its leadership team with new senior vice president appointments.
At the American Association for Cancer Research (AACR) 2025 Annual Meeting in Chicago, Cogent Biosciences, Inc. (COGT) shared notable advancements from its preclinical oncology pipeline. The company's presentations highlighted significant progress in four targeted therapy programs. The pan KRAS(ON) inhibitor demonstrated remarkable efficacy, achieving a 90% tumor growth inhibition in preclinical mouse models with a 30mg/kg oral dose.
Cogent also detailed results from other promising drug candidates including CGT6297, a PI3K? inhibitor targeting mutations such as H1047R, which has shown broad cellular profiling efficacy across various resistant cell lines. Meanwhile, CGT4859, a selective FGFR2/3 inhibitor, is currently in Phase 1 trials, indicating complete tumor regression at doses greater than 2.5 mg/kg in preclinical studies. Another key program, CGT4255, an ErbB2 inhibitor, showed significant brain penetration properties.
In addition to preclinical advancements, Cogent Biosciences announced strategic leadership changes. Ray Frost joins as Senior Vice President of Market Access and Dr. Adam Boyd becomes Senior Vice President of Corporate Strategy, strengthening the company's executive team. Moreover, Cogent granted inducement equity awards to five new employees, including 446,000 shares with a four-year vesting schedule, as part of its 2020 Inducement Plan, adhering to Nasdaq's Listing Rule 5635(c)(4).
As Cogent continues to propel its targeted therapies for genetically defined diseases, these developments underscore the company's commitment to innovation in oncology treatments.
